The FDA has approved RHA Redensity Eye, a crosslinked hyaluronic acid filler from Revance and Teoxane, for correction of under-eye hollowing and volume loss. The indication extends the RHA line—known for its resilient, dynamic properties—into the periorbital space, a technically demanding zone where filler migration and Tyndall effect are persistent concerns.
Injectables
RHA Redensity Eye Wins FDA Nod for Under-Eye Hollows
Revance and Teoxane's crosslinked HA filler gains clearance for periorbital volume loss—expanding the RHA platform beyond lips and cheeks.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
RHA Redensity Eye extends the dynamic-filler platform into the periorbital space.
RHA's rheology profile, engineered to mimic native HA behavior during facial movement, addresses a real clinical friction point: traditional fillers often appear static or overfilled in the tear trough. The under-eye market remains fragmented—Restylane, Juvéderm, and Belotero each hold territory—but a purpose-built formulation for that anatomy could shift preference. Revance now has a three-product injectable suite (Nuceiva toxin, RHA for lips/cheeks, and now RHA Redensity Eye), strengthening its position as an alternative to AbbVie and Galderma for practices seeking non-Allergan/non-Galderma platforms.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.